Fig. 4: Nano-reshaper improved systemic immune response in GBM-bearing mice.
From: Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
a Orthotopic tumor implantation and treatment scheme for 5% Glu, ApoE-CaCP, ApoE-pLIGHT@CaP and Nano-reshaper therapy. Thymus index (b) and spleen index (c) of intracranial GL261 GBM-bearing mice receiving various formulations on day 15 (n = 5 mice). CD8+ and CD4+ T cells in spleens (d), peripheral blood (g), and DLNs (k) collected from GL261-bearing mice receiving various formulations on day 15 (n = 3 mice). CD8 and CD4 T cell counts in spleens (e), peripheral blood (h), and DLNs (l) obtained from intracranial GL261 GBM-bearing mice receiving various formulations on day 15 (n = 3 mice). Activation status of CD8+ T cells in spleens (f), peripheral blood (i), and DLNs (m) was analyzed by staining for IFN-γ and GzmB after receiving various formulations on day 15 (n = 3 mice). Trp-2 specific CD8+ T cells in blood (j) and CD80+CD86+ DCs in DLNs (n) obtained from intracranial GL261 GBM-bearing mice receiving various formulations on day 15 (n = 3 mice). Data were shown as mean ± SD. Error bars represent SD. Significant differences were evaluated in b–n using one-way ANOVA with Tukey multiple comparisons post-test. Source data are provided as a Source Data file.
